[The first Italian patient affected by diffuse large B-cell lymphoma treated with axi-cel in the second line: innovation and tradition.].

• Tác giả: Stefania Bramanti, Davide Chizzoniti, Daniele Mannina
• Ngôn ngữ: eng
• Ký hiệu phân loại: 133.526 First six signs
• Thông tin xuất bản: Italy : Recenti progressi in medicina , 2025
• Bộ sưu tập: NCBI
• ID: 52181

Tóm tắt

CAR-T cell therapy has revolutionized the treatment of refractory or relapsed diffuse large B-cell lymphoma (DLBCL) within 12 months, replacing the use of high-dose chemotherapy with autologous stem cell reinfusion. Primary chemoresistance remains one of the most unfavorable prognostic scenarios for patients with DLBCL, despite the progress made with the introduction of anti-CD20 monoclonal antibodies in first-line treatment. Early identification of prognostic factors associated with clinical presentation represents an integrated approach that ensures rapid access to autologous anti-CD19 CAR-T therapy in selected cases that may benefit from treatment according to current standard indications.